Protara Shares Sink After Pricing $75 Million Public Offering

Dow Jones

Dec 05, 2025

By Connor Hart

Shares of Protara Therapeutics fell after the company priced a $75 million public offering of common stock.

The stock fell 15%, to $5.86, in premarket trading Friday. Through Thursday's close, shares have gained more than 30% so far this year.

The drugmaker said late Thursday that it plans to sell about 13 million shares of its common stock at $5.75 apiece. Protara will also grant underwriters a 30-day option to purchase up to an additional nearly 2 million shares at the offering price, minus discounts and commissions.

Gross proceeds from the offering are expected to be approximately $75 million, and the company intends to use net proceeds to fund the clinical development of investigational cell therapy TARA-002, as well as the development of other clinical programs.

Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

December 05, 2025 06:48 ET (11:48 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2589891776"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589891776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589891776?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589891776","market":"other","top_or_hot":-1,"title":"Protara Shares Sink After Pricing $75 Million Public Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Protara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell after the company priced a $75 million public offering of common stock. \n</p>\n<p>\n  The stock fell 15%, to $5.86, in premarket trading Friday. Through Thursday's close, shares have gained more than 30% so far this year. \n</p>\n<p>\n  The drugmaker said late Thursday that it plans to sell about 13 million shares of its common stock at $5.75 apiece. Protara will also grant underwriters a 30-day option to purchase up to an additional nearly 2 million shares at the offering price, minus discounts and commissions. \n</p>\n<p>\n  Gross proceeds from the offering are expected to be approximately $75 million, and the company intends to use net proceeds to fund the clinical development of investigational cell therapy TARA-002, as well as the development of other clinical programs. \n</p>\n<p>\n  Protara may also use the net proceeds from the offering for working capital and other general corporate purposes. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 05, 2025 06:48 ET (11:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Protara Shares Sink After Pricing $75 Million Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProtara Shares Sink After Pricing $75 Million Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-05 19:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Protara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell after the company priced a $75 million public offering of common stock. \n</p>\n<p>\n  The stock fell 15%, to $5.86, in premarket trading Friday. Through Thursday's close, shares have gained more than 30% so far this year. \n</p>\n<p>\n  The drugmaker said late Thursday that it plans to sell about 13 million shares of its common stock at $5.75 apiece. Protara will also grant underwriters a 30-day option to purchase up to an additional nearly 2 million shares at the offering price, minus discounts and commissions. \n</p>\n<p>\n  Gross proceeds from the offering are expected to be approximately $75 million, and the company intends to use net proceeds to fund the clinical development of investigational cell therapy TARA-002, as well as the development of other clinical programs. \n</p>\n<p>\n  Protara may also use the net proceeds from the offering for working capital and other general corporate purposes. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 05, 2025 06:48 ET (11:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2589891776","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589891776","pubTimestamp":1764935280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Protara Therapeutics fell after the company priced a $75 million public offering of common stock.The stock fell 15%, to $5.86, in premarket trading Friday. Through Thursday's close, shares have gained more than 30% so far this year.The drugmaker said late Thursday that it plans to sell about 13 million shares of its common stock at $5.75 apiece. Protara will also grant underwriters a 30-day option to purchase up to an additional nearly 2 million shares at the offering price, minus discounts and commissions.Gross proceeds from the offering are expected to be approximately $75 million, and the company intends to use net proceeds to fund the clinical development of investigational cell therapy TARA-002, as well as the development of other clinical programs.Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TARA":"ArTara Therapeutics, Inc."},"translate_title":"Protara公开发行7500万美元后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TARA":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Protara Therapeutics fell after the company priced a $75 million public offering of common stock. \n\n\n  The stock fell 15%, to $5.86, in premarket trading Friday. Through Thursday's close, shares have gained more than 30% so far this year. \n\n\n  The drugmaker said late Thursday that it plans to sell about 13 million shares of its common stock at $5.75 apiece. Protara will also grant underwriters a 30-day option to purchase up to an additional nearly 2 million shares at the offering price, minus discounts and commissions. \n\n\n  Gross proceeds from the offering are expected to be approximately $75 million, and the company intends to use net proceeds to fund the clinical development of investigational cell therapy TARA-002, as well as the development of other clinical programs. \n\n\n  Protara may also use the net proceeds from the offering for working capital and other general corporate purposes. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 05, 2025 06:48 ET (11:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}